Cabanillas ME, McFadden DG, Durante C (2016) Thyroid cancer. Lancet 388(10061):2783–2795

Article  CAS  PubMed  Google Scholar 

Volante M, Lam AK, Papotti M, Tallini G (2021) Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 32(1):63–76

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radkay LA, Chiosea SI, Seethala RR, Hodak SP, LeBeau SO, Yip L, McCoy KL, Carty SE, Schoedel KE, Nikiforova MN, Nikiforov YE, Ohori NP (2014) Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 122(12):873–882

Article  CAS  PubMed  Google Scholar 

Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC (2020) Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 30(9):1288–1296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH (2019) KRAS G12V mutation in acquired resistance to combined BRAF and MEK inhibition in papillary thyroid cancer. J Natl Compr Canc Netw 17(5):409–413

Article  PubMed  PubMed Central  Google Scholar 

Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD (2014) Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 74(24):7430–7441

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong Z, Xue L, Wei M, Liu Z, Vlantis AC, van Hasselt CA, Chan JYK, Li D, Zeng X, Tong MCF, Chen GG (2021) The knockdown of Nrf2 suppressed tumor growth and increased the sensitivity to lenvatinib in anaplastic thyroid cancer. Oxid Med Cell Longev 2021:3900330

Article  PubMed  PubMed Central  Google Scholar 

Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ (2021) FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast Cancer Res 23(1):21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Baum RP, Prasad V, Hommann M (2012) Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 5(3):187–194

PubMed  PubMed Central  Google Scholar 

Cai SJ, Liu Y, Han S, Yang C (2019) Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci 9:45

Article  PubMed  PubMed Central  Google Scholar 

Pozdeyev N, Rose MM, Bowles DW, Schweppe RE (2020) Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol 61:23–29

Article  PubMed  PubMed Central  Google Scholar 

Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13(3):184–199

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE (2013) Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 98(11):E1852–E1860

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Luo XX, Kim GD, Liu Y, Xue Z, Zhang L, Shu Y, Yang T, Chen Y, Zhang S, Chen H, Zhang W, Li R, Tang H, Dong B, Xianghui F, Cheng W, Zhang W, Yang L, Peng Y, Dai L, Hongbo H, Jiang Y, Gong C, Yiguo H, Zhu J, Li Z, Caulin C, Wei T, Park J, Heng X (2021) Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv 7:eabf3657

Article  PubMed  PubMed Central  Google Scholar 

Saiselet M, Floor S, Tarabichi M, Dom G, Hebrant A, van Staveren WC, Maenhaut C (2012) Thyroid cancer cell lines: an overview. Front Endocrinol (Lausanne) 3:133

Article  CAS  PubMed  Google Scholar 

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93(11):4331–4341

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE (2019) Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin Cancer Res 25(10):3141–3151

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan LN, Ma YF, Li Z, Hu JA, Xu ZH (2021) KRAS G12V mutation upregulates PD-L1 expression via TGF-beta/EMT signaling pathway in human non-small-cell lung cancer. Cell Biol Int 45(4):795–803

Article  CAS  PubMed  Google Scholar 

Monticone M, Biollo E, Maffei M, Donadini A, Romeo F, Storlazzi CT, Giaretti W, Castagnola P (2008) Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer 7:92

Article  PubMed  PubMed Central  Google Scholar 

McCormick F (2015) KRAS as a therapeutic target. Clin Cancer Res 21(8):1797–1801

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu P, Wang Y, Li X (2019) Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B 9(5):871–879

Article  PubMed  PubMed Central  Google Scholar 

Uprety D, Adjei AA (2020) KRAS: from undruggable to a druggable cancer target. Cancer Treat Rev 89:102070

Article  CAS  PubMed  Google Scholar 

Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O’Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781):217–223

Article  CAS  PubMed  Google Scholar 

Robledinos-Antón N, Fernández-Ginés R, Manda G, Cuadrado A (2019) Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid Med Cell Longev 2019:1–20

Article  Google Scholar